These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 12036922)
21. YHHU0895, a novel synthetic small-molecule microtubule-destabilizing agent, effectively overcomes P-glycoprotein-mediated tumor multidrug resistance. Zhao H; Quan H; Xie C; Xu Y; Xie F; Hu Y; Lou L Cancer Lett; 2012 Jan; 314(1):54-62. PubMed ID: 21982683 [TBL] [Abstract][Full Text] [Related]
22. 9-Benzylidene-naphtho[2,3-b]thiophen-4-ones as novel antimicrotubule agents-synthesis, antiproliferative activity, and inhibition of tubulin polymerization. Zuse A; Schmidt P; Baasner S; Böhm KJ; Müller K; Gerlach M; Günther EG; Unger E; Prinz H J Med Chem; 2006 Dec; 49(26):7816-25. PubMed ID: 17181164 [TBL] [Abstract][Full Text] [Related]
23. Concise synthesis and structure-activity relationships of combretastatin A-4 analogues, 1-aroylindoles and 3-aroylindoles, as novel classes of potent antitubulin agents. Liou JP; Chang YL; Kuo FM; Chang CW; Tseng HY; Wang CC; Yang YN; Chang JY; Lee SJ; Hsieh HP J Med Chem; 2004 Aug; 47(17):4247-57. PubMed ID: 15293996 [TBL] [Abstract][Full Text] [Related]
24. Arylthioindoles, potent inhibitors of tubulin polymerization. De Martino G; La Regina G; Coluccia A; Edler MC; Barbera MC; Brancale A; Wilcox E; Hamel E; Artico M; Silvestri R J Med Chem; 2004 Dec; 47(25):6120-3. PubMed ID: 15566282 [TBL] [Abstract][Full Text] [Related]
25. Expression of beta-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-Anticancer Drug Screen: correlation with sensitivity to microtubule active agents. Nicoletti MI; Valoti G; Giannakakou P; Zhan Z; Kim JH; Lucchini V; Landoni F; Mayo JG; Giavazzi R; Fojo T Clin Cancer Res; 2001 Sep; 7(9):2912-22. PubMed ID: 11555610 [TBL] [Abstract][Full Text] [Related]
26. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone. Lee FY; Smykla R; Johnston K; Menard K; McGlinchey K; Peterson RW; Wiebesiek A; Vite G; Fairchild CR; Kramer R Cancer Chemother Pharmacol; 2009 Jan; 63(2):201-12. PubMed ID: 18350296 [TBL] [Abstract][Full Text] [Related]
27. Synthesis and biological evaluation of 2,4,5-substituted pyrimidines as a new class of tubulin polymerization inhibitors. Xie F; Zhao H; Li D; Chen H; Quan H; Shi X; Lou L; Hu Y J Med Chem; 2011 May; 54(9):3200-5. PubMed ID: 21480626 [TBL] [Abstract][Full Text] [Related]
28. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo. Schwock J; Pham NA; Cao MP; Hedley DW Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866 [TBL] [Abstract][Full Text] [Related]
30. A novel oral indoline-sulfonamide agent, N-[1-(4-methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-isonicotinamide (J30), exhibits potent activity against human cancer cells in vitro and in vivo through the disruption of microtubule. Liou JP; Hsu KS; Kuo CC; Chang CY; Chang JY J Pharmacol Exp Ther; 2007 Oct; 323(1):398-405. PubMed ID: 17660383 [TBL] [Abstract][Full Text] [Related]
31. Methoxy-substituted 3-formyl-2-phenylindoles inhibit tubulin polymerization. Gastpar R; Goldbrunner M; Marko D; von Angerer E J Med Chem; 1998 Dec; 41(25):4965-72. PubMed ID: 9836614 [TBL] [Abstract][Full Text] [Related]
32. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466 [TBL] [Abstract][Full Text] [Related]
33. Novel benzylidene-9(10H)-anthracenones as highly active antimicrotubule agents. Synthesis, antiproliferative activity, and inhibition of tubulin polymerization. Prinz H; Ishii Y; Hirano T; Stoiber T; Camacho Gomez JA; Schmidt P; Düssmann H; Burger AM; Prehn JH; Günther EG; Unger E; Umezawa K J Med Chem; 2003 Jul; 46(15):3382-94. PubMed ID: 12852768 [TBL] [Abstract][Full Text] [Related]
34. Identification and characterization of A-105972, an antineoplastic agent. Wu-Wong JR; Alder JD; Alder L; Burns DJ; Han EK; Credo B; Tahir SK; Dayton BD; Ewing PJ; Chiou WJ Cancer Res; 2001 Feb; 61(4):1486-92. PubMed ID: 11245455 [TBL] [Abstract][Full Text] [Related]
35. Preclinical discovery of ixabepilone, a highly active antineoplastic agent. Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795 [TBL] [Abstract][Full Text] [Related]
36. Design, synthesis, and biological evaluation of thiophene analogues of chalcones. Romagnoli R; Baraldi PG; Carrion MD; Cara CL; Cruz-Lopez O; Preti D; Tolomeo M; Grimaudo S; Di Cristina A; Zonta N; Balzarini J; Brancale A; Sarkar T; Hamel E Bioorg Med Chem; 2008 May; 16(10):5367-76. PubMed ID: 18440234 [TBL] [Abstract][Full Text] [Related]
37. 7-Aroyl-aminoindoline-1-sulfonamides as a novel class of potent antitubulin agents. Chang JY; Hsieh HP; Chang CY; Hsu KS; Chiang YF; Chen CM; Kuo CC; Liou JP J Med Chem; 2006 Nov; 49(23):6656-9. PubMed ID: 17154496 [TBL] [Abstract][Full Text] [Related]
38. [4-(imidazol-1-yl)thiazol-2-yl]phenylamines. A novel class of highly potent colchicine site binding tubulin inhibitors: synthesis and cytotoxic activity on selected human cancer cell lines. Mahboobi S; Sellmer A; Höcher H; Eichhorn E; Bär T; Schmidt M; Maier T; Stadlwieser JF; Beckers TL J Med Chem; 2006 Sep; 49(19):5769-76. PubMed ID: 16970401 [TBL] [Abstract][Full Text] [Related]
39. Tubulin-perturbing naphthoquinone spiroketals. Balachandran R; Hopkins TD; Thomas CA; Wipf P; Day BW Chem Biol Drug Des; 2008 Feb; 71(2):117-24. PubMed ID: 18194192 [TBL] [Abstract][Full Text] [Related]
40. Antiangiogenic and antitumoral activity of phenyl-3-(2-chloroethyl)ureas: a class of soft alkylating agents disrupting microtubules that are unaffected by cell adhesion-mediated drug resistance. Petitclerc E; Deschesnes RG; Côté MF; Marquis C; Janvier R; Lacroix J; Miot-Noirault E; Legault J; Mounetou E; Madelmont JC; C -Gaudreault R Cancer Res; 2004 Jul; 64(13):4654-63. PubMed ID: 15231678 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]